Petrelintide

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Petrelintide has not been approved by the FDA for any indication. It is under active clinical investigation (Phase 2 completed, Phase 3 planned for H2 2026 per Roche/Zealand Pharma public statements). No New Drug Application has been filed as of May 2026. Supply and use outside of FDA-registered clinical trials is not authorised.

No verifiable third-party COA path in this market

Transparent blend · bci-1.0 · never paid-placement

Primary name

Petrelintide

Origin

Synthetic 36-amino-acid acylated peptide derived from the sequence of human amylin (islet amyloid polypeptide, IAPP), engineered by Zealand Pharma. Key structural modifications include replacement of the native disulfide bond with a lactam bridge for enhanced stability, deletion or substitution of deamidation-prone asparagine residues (positions 3, 14, 21–22, 31, 35), and conjugation of a C20 fatty-acid chain to confer the approximately 10-day terminal half-life enabling once-weekly subcutaneous dosing. PubChem CID 172915807; molecular formula C185H305N49O61; MW ~4192 Da.

Registry IDs

PubChem CID

172915807

InChIKey

TVOIUFVYEVVHCS-HJODGROVSA-N

Molecular formula

C185H305N49O61

Molar mass

4192 g/mol

Monoisotopic

4189.2270527 Da

InChIKey

TVOIUFVYEVVHCS-HJODGROVSA-N

Appearance

White to off-white lyophilised powder (typical for long-chain acylated peptides of ~4.2 kDa molecular weight)

Solubility

Soluble in aqueous buffers near physiological pH; C20 fatty-acid conjugation req…

Sequence not available in current seed.

Stability: Chemical stability at neutral pH was a primary design objective; the lactam bridge eliminates disulfide-linked fibrillation risk inherent to native amylin; aspa

Vial sizes

null mg

Purity grades

research grade

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Petrelintide acts as a potent agonist at amylin receptors (primarily AMY3R), heterodimeric complexes formed between the calcitonin receptor (CTR) and receptor activity-modifying protein 3 (RAMP3), with additional activity at AMY1R
• Receptor engagement in the brainstem area postrema activates cAMP-mediated intracellular signalling cascades that reduce food intake by transmitting postprandial satiety signals, suppress postprandial glucagon secretion, and slow gastric emptying
• The lactam bridge replacing the natural disulfide bond maintains AMY3R functional potency while preventing fibrillation at neutral pH that limits the therapeutic utility of native amylin
• Acylation-mediated albumin binding prolongs circulating exposure without altering the amylin-like receptor-binding mode

Pharmacokinetics (ADME)

Half-life

~240 hours (~10 days); terminal half-life supporting once-weekly subcutaneous dosing (Phase 1 data, PMID 42017294)

Clearance

Not fully characterised publicly; presumed proteolytic and renal clearance consistent with acylated peptide class; dose-proportional PK from 0.6 mg to 9.0 mg with Tmax ~24 h post-dose

PK–PD note: Subcutaneous bioavailability ~85% in Phase 1 studies; steady-state reached after approximately 4–5 weeks of weekly dosing; renal impairment PK characterised in a dedicated Phase 1 trial (NCT07076030)…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

5 registered trials — 0 currently recruiting.

Phase 2
NCT07589686
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

NOT_YET_RECRUITING

Phase 1
NCT07338214
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

COMPLETED

Phase 2
NCT06662539
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

COMPLETED

Phase 1
NCT07076030
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

COMPLETED

Phase 2
NCT06926842
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

ACTIVE_NOT_RECRUITING

Summary (literature)

Across Phase 1 and Phase 2 studies, petrelintide has demonstrated a tolerability profile described as placebo-like. In the 16-week Phase 1b multiple-ascending-dose study (PMID 42017294), no serious or severe treatment-emergent adverse events (TEAEs) were observed. Gastrointestina…

WADA status

Not specifically listed by name on the 2026 WADA Prohibited List. Amylin analogues are not currently enumerated as a named class under S2 (Peptide Hormones, Gro…

Dominant research route: Subcutaneous (SC)

Humans (Phase 1 SAD 0.04–2.4 mg; Phase 1 MAD 0.6–9.0 mg once-weekly; Phase 2 ZUPREME-1/ZUPREME-2) and rats (single SC bolus 30 nmol/kg)

Bioavailability: Subcutaneous bioavailability reported as approximately 85%; Tmax ~24 h; terminal half-life ~240 h (~10 days) in humans, supporting once-weekly dosing; dose-proportional PK over 0.6–9 mg

Dominant route across all clinical development; designed as a long-acting acylated amylin analogue for once-weekly SC injection. Rat single-dose SC PK showed Tmax ~24 h and terminal half-life ~34 h, projected to translate to once-weekly human dosing.

Humans (Phase 1 SAD trial included a 0.35 mg intravenous dose)

Bioavailability: IV dose used as reference arm to determine absolute SC bioavailability (~85%); no standalone IV therapeutic development

IV administration studied only as a single low reference dose within the Phase 1 SAD trial to enable absolute bioavailability calculation for the SC route; not intended as a therapeutic route.

Rats (Sprague–Dawley; single SC bolus 30 nmol/kg; plasma sampled over 7 days via LC-MS/MS)

Bioavailability: In rats: Tmax ~24 h; terminal half-life ~34 h (peptides with pI <5 had half-lives >30 h); slow absorption consistent with albumin-binding acylated design

Preclinical SC PK in rats underpinned the once-weekly human dosing projection; reduced renal clearance attributed to reversible albumin binding via the fatty-acid moiety.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Researched storefront prices, bucketed

What each test proves — general guidance, plus this compound's researched purity data

Independent labs cited for this compound

No recalls, seizures, warning letters, or enforcement actions identified for petrelintide (ZP8396). Compound remains investigational (Phase 1/2) under Zealand Pharma; no FDA-approved product exists to recall as of retrieved sources.

Buyer red-flag checklist

• Petrelintide is an investigational peptide (ZP8396, Zealand Pharma) with no FDA-approved drug product; any commercial sale as a 'research peptide' is outside the regulated drug development pipeline.
• No independent third-party purity/identity testing of petrelintide located in public sources.
• No FDA import alerts, warning letters, or enforcement actions found — absence of enforcement does not imply quality assurance for non-pharmaceutical sources.
• Compound is chemically distinct from approved amylin analog pramlintide; cross-contamination or mislabeling risk exists in unregulated supply chains.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent lab testing (Janoshik/MZ Biolabs/Finnrick) of petrelintide identified. As an investigational peptide not commercially distributed, no aggregate underdosing data exists.

• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not specifically listed on the WADA Prohibited List. Petrelintide is an investigational amylin analog; amylin analogs (e.g., pramlintide) are not enumerated substances under the current WADA Prohibited List. No WADA scheduling action identified for petrelintide as of retrieved sources.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• early-stage-hype
• comparison-driven-speculation
• no-real-world-experience
• investor-pipeline-framing

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Investigational once-weekly amylin analogue (DACRA) in Phase 2 for obesity; achieved ~10.7% weight loss with placebo-like GI tolerability in the ZUPREME-1 trial. Approximately 4 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Investigational — no FDA approval. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet